标准化方法比较银屑病临床试验与真实世界人群的治疗安全性和有效性结局
本研究将BADBIR注册数据与两项乌司奴单抗随机对照试验(RCT)的个体参与者数据合并,用多变量逻辑回归和倾向评分加权标准化真实世界人群至试验人群分布。共纳入6790例注册和2021例RCT参与者,模型C统计量0.82(95%CI 0.81-0.83)。加权后严重不良事件(SAE)发生率风险差为9.27/1000人年(95%CI -3.91-22.5),6个月PASI<1.5比例风险差为0.95(95%CI -1.98-4.15)。结论认为RCT人群不能完全代表真实世界,但这种外部有效性缺失不能解释疗效-效果差距。
要点
- 基线特征可预测患者是否适合纳入银屑病生物制剂RCT,模型C统计量0.82。
- 标准化加权后RCT与真实世界人群的SAE发生率和PASI<1.5比例风险差均无统计学意义。
- RCT外部有效性不足不能解释疗效-效果差距,观察者效应和依从性等因素可能更重要。
核心结论
- 银屑病生物制剂RCT人群不能完全代表真实世界人群,但这种外部有效性缺失不能解释疗效-效果差距。
研究设计与样本
- 将BADBIR注册数据附加到两项评估乌司奴单抗的RCT个体参与者数据,共纳入6790例注册和2021例RCT参与者。
- 用多变量逻辑回归评估基线变量与RCT纳入的关联,并计算倾向评分权重将注册人群重新加权至试验人群分布。
- 计算以试验状态为因变量的模型C统计量,并比较加权前后BADBIR队列第一年SAE发生率和6个月后PASI的风险差。
主要发现
- 多变量逻辑回归模型C统计量为0.82(95%CI 0.81-0.83)。
- 加权后SAE发生率风险差为9.27/1000人年(95%CI -3.91-22.5)。
- 加权后PASI<1.5患者比例风险差为0.95(95%CI -1.98-4.15)。
临床怎么用
- 解读银屑病生物制剂RCT结果时需考虑其人群与真实世界存在差异,但该差异不直接导致疗效-效果差距。
- 真实世界疗效差异可能更多源于观察者效应和用药依从性等非基线因素,而非患者基线特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are associated with being included in a psoriasis RCT. Secondly, to estimate the differences in the incidence of severe adverse events (SAEs) and the response rate between RCT and real-world populations of patients on biologic therapies for psoriasis using a standardization method. METHODS: Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) were appended to individual participant-level data from two RCTs assessing ustekinumab in patients with psoriasis. Baseline variables were assessed for association of being in an RCT using a multivariable logistic regression model. Propensity score weights were derived to reweigh the registry population so that variables had the distribution of the trial population. We measured the C-statistic of the model with trial status as the dependent variable, and the risk differences in the incidence rate of SAEs in the first year and Psoriasis Area and Severity Index (PASI) after 6 months in the BADBIR cohort before and after weighting. RESULTS: In total 6790 registry and 2021 RCT participants were included. The multivariable logistic regression model had a C-statistic of 0.82 [95% confidence interval (CI) 0.81-0.83]. The risk differences for the incidence rate of SAEs and the proportion of patients with PASI < 1.5 were 9.27 (95% CI -3.91-22.5) per 1000 person-years and 0.95 (95% CI -1.98-4.15), respectively. CONCLUSIONS: Our results suggest that RCTs of biologic therapies in patients with psoriasis are not fully representative of the real-world population, but this lack of external validity does not account for the efficacy-effectiveness gap. What's already known about this topic? Patients with psoriasis who would not be eligible for randomized controlled trials (RCTs) investigating biologic therapies have a greater risk of serious adverse events and lower treatment effectiveness than patients who would have been eligible. What does this study add? Baseline patient characteristics were shown to be predictive of whether a patient would have been eligible for enrolment in an RCT for psoriasis biologic therapy. We did not find any efficacy-effectiveness gap between the sample representative of the real-world population of patients with psoriasis and the sample representative of the RCT population. Factors outside of baseline patient characteristics, such as observer effect and higher adherence in RCTs, may be more influential in any efficacy-effectiveness gap between trial and real-world populations of patients with psoriasis.
引用
- Yiu ZZN, Mason KJ, Barker JNWN, et al. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Br J Dermatol. 2019. PMID: 30822358. doi:10.1111/bjd.17849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。